Biolife Solutions, Inc. (OTCMKTS:BLFS) Caught in Reverse Current
Biolife Solutions, Inc. (OTCMKTS:BLFS) is yet another biopharmaceutical stunner, which now faced a cliff drop of selling. BLFS fell by more than 26% to $1.07, on dollar volumes above $628,000. The rise in BLFS was on relatively modest dollar volumes, and we looked at it last in August, when the ticker was a bit below 90 cents. While the rising trend looked good in August, it grew even steeper in September and October, and this made the positions of BLFS much shakier. 
BLFS has not come in with a promotion or a new press release since the end of September, and what caused the selling is not immediately clear. BLFS held great promise for improved earnings in the later half of the year, but the lack of news pushed the shares down. 
The latest mention of treatments in development came at the end of September, when BLFS updated on the clinical usage of its proprietary cryopreservation technology. BLFS has the major advantage of offering a technology that is essential in may medical fields, instead of aiming for a novel product that may have to wait before being applied in practices.
BLFS, according to its latest filings, is equipped with the following financials:
- $76,205 cash
- $1.8 million total current assets
- $1.4 million total current liabilities
- $2.33 million product sales
- $82,844 net loss
BLFS is another addition to a market that is rather hungry for pharmaceutical shares making a breakthrough. Several climbers reached a similar position, only to correct suddenly.
International Stem Cell Corp. (OTCMKTS:ISCO) reached a peak at 22 cents, but went on to slide to 15 cents on a few days of selling.
Biozone Pharmaceuticals, Inc. (OTCBB:BZNE) is still hopeful despite days of selling, growing again in the past two days to 79 cents. The company burst to activity after the entrance of a large investor, Dr. Phillip Frost, who may have recognized the potential of the company.
For BLFS, the days will certainly change, as the ticker has seen setbacks before. At around a dollar, the stock is not guaranteed a better or worse future. Still, keep in mind that pressures to sell may increase. If you still believe BLFS can be bought at a bargain price, be sure you can afford a run down to baseline levels.
